Evidence map›Paper›PMID 37346072›Full record

ArticleFrontiers in oncology2023

Complete prevalence and indicators of cancer cure: enhanced methods and validation in Italian population-based cancer registries.

Federica Toffolutti, Stefano Guzzinati, Angela De Paoli, Silvia Francisci, Roberta De Angelis, Emanuele Crocetti, Laura Botta, Silvia Rossi, Sandra Mallone, Manuel Zorzi and 33 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. PalpableWorld journal of clinical oncology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors.

Federica ToffoluttiCancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy.
Stefano GuzzinatiEpidemiological Department, Azienda Zero, Padua, Italy.
Angela De PaoliEpidemiological Department, Azienda Zero, Padua, Italy.
Silvia FrancisciNational Centre for Disease Prevention and Health Promotion, National Institute of Health, Rome, Italy.
Roberta De AngelisDepartment of Oncology and Molecular Medicine, National Institute of Health, Rome, Italy.
Emanuele CrocettiCancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy.
Laura BottaEvaluative Epidemiology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Silvia RossiDepartment of Oncology and Molecular Medicine, National Institute of Health, Rome, Italy.
Sandra MalloneNational Centre for Disease Prevention and Health Promotion, National Institute of Health, Rome, Italy.
Manuel ZorziEpidemiological Department, Azienda Zero, Padua, Italy.
Gianfranco ManneschiTuscany Cancer Registry, Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Ettore BidoliCancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy.
Alessandra RavaioliEmilia-Romagna Cancer Registry, Romagna Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Forlì, Italy.
Francesco CuccaroRegistro Tumori Puglia - Sezione Azienda Sanitaria Locale (ASL) Barletta-Andria-Trani, Epidemiologia e Statistica, Barletta, Italy.
Enrica MigliorePiedmont Cancer Registry, Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica (CPO) Piemonte and University of Turin, Turin, Italy.
Antonella PuppoLiguria Cancer Registry, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Margherita FerranteRegistro tumori integrato di Catania-Messina-Enna, Igiene Ospedaliera, Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco, Catania, Italy.
Cinzia GasparottiStruttura Semplice Epidemiologia, Agenzia di Tutela della Salute (ATS) Brescia, Brescia, Italy.
Maria GambinoRegistro tumori ATS Insubria (Provincia di Como e Varese) Responsabile S.S. Epidemiologia Registri Specializzati e Reti di Patologia, Varese, Italy.
Giuliano CarrozziEmilia-Romagna Cancer Registry, Modena Unit, Public Health Department, Local Health Authority, Modena, Italy.
Fabrizio StracciUmbria Cancer Registry, Public Health Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Maria MichiaraEmilia-Romagna Cancer Registry, Parma Unit, Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Rossella CavalloCancer Registry Azienda Sanitaria Locale (ASL) Salerno- Dipartimento di Prevenzione, Salerno, Italy.
Walter MazzuccoClinical Epidemiology and Cancer Registry Unit, Azienda Ospedaliera Universitaria Policlinico (AOUP) di Palermo, Palermo, Italy.
Mario FuscoRegistro Tumori ASL Napoli 3 Sud, Napoli, Italy.
Paola BallotariOsservatorio Epidemiologico, ATS Val Padana, Mantova, Italy.
Giuseppe SampietroServizio Epidemiologico ATS di Bergamo, Bergamo, Italy.
Stefano FerrettiEmilia-Romagna Cancer Registry, Ferrara Unit, Local Health Authority, Ferrara, and University of Ferrara, Ferrara, Italy.
Lucia MangoneEmilia-Romagna Cancer Registry, Reggio Emilia Unit, Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Roberto Vito RizzelloTrento Province Cancer Registry, Unit of Clinical Epidemiology, Trento, Italy.
Michael MianInnovation, Research and Teaching Service (SABES-ASDAA), Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität, Bolzano-Bozen, Italy.
Giuseppe CasconeAzienda Sanitaria Provinciale (ASP) Ragusa - Dipartimento di Prevenzione -Registro Tumori, Ragusa, Italy.
Lorenza BoschettiCancer Registry of the Province of Pavia, Pavia, Italy.
Rocco GalassoUnit of Regional Cancer Registry, Clinical Epidemiology and Biostatistics, IRCCS Centro di Riferimento Oncologico di Basilicata (CROB), Rionero in Vulture, Italy.
Daniela PirasNord Sardegna Cancer Registry, ASL, Sassari, Italy.
Maria Teresa PesceMonitoraggio rischio ambientale e Registro Tumori ASL Caserta, Caserta, Italy.
Francesca BellaSiracusa Cancer Registry, Provincial Health Authority of Siracusa, Siracusa, Italy.
Pietro SeghiniEmilia-Romagna Cancer Registry, Piacenza Unit, Public Health Department, AUSL Piacenza, Piacenza, Italy.
Anna Clara FanettiSondrio Cancer Registry, Agenzia di Tutela della Salute della Montagna, Sondrio, Italy.
Pasquala PinnaNuoro Cancer Registry, RT Nuoro, Servizio Igiene e Sanità Pubblica, ASL Nuoro, Nuoro, Italy.
Diego SerrainoCancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy.
Luigino Dal MasoCancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy.
AIRTUM Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To describe the procedures to derive complete prevalence and several indicators of cancer cure from population-based cancer registries. Materials and methods: Cancer registry data (47% of the Italian population) were used to calculate limited duration prevalence for 62 cancer types by sex and registry. The incidence and survival models, needed to calculate the completeness index ( Results: For the most frequent cancer types, the Weibull survival model stratified by sex and age showed a very good fit with observed survival. For men diagnosed with any cancer type at age 65-74 years, CF was 41%, while the NS was 49% until age 100 and 50% until age 90. In women, similar differences emerged for patients with any cancer type or with breast cancer. Among patients alive in 2018 with colorectal cancer at age 55-64 years, 48% were already cured (had reached their specific TTC), while the cure prevalence (lifelong probability to be cured from cancer) was 89%. Cure prevalence became 97.5% (2.5% will die because of their neoplasm) for patients alive >5 years after diagnosis. Conclusions: This study represents an addition to the current knowledge on the topic providing a detailed description of available indicators of prevalence and cancer cure, highlighting the links among them, and illustrating their interpretation. Indicators may be relevant for patients and clinical practice; they are unambiguously defined, measurable, and reproducible in different countries where population-based cancer registries are active.

Indexed as

cancer cure indicatorscure fractioncure prevalenceItalyprevalencesurvivaltime to cure

Identifiers

PMID37346072
PMCPMC10280813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.